2 completed, 2 recruiting, 1 terminated, 1 unknown. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 2, Recruiting 2, Terminated 1, Unknown 1 |
Follow AIS: new trials by email Literature Review of AIS trials Research Report on AIS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset. BXOS110, placebo - AIS | Phase 3 | Recruiting | Biocells (Beijing) Biotech Co.,Ltd | 1112 | 2026-01-19 | 2026-04-09 |
| A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha), Placebo - Cervical Cancer, Genital Wart | Phase 3 | Terminated | Shanghai Bovax Biotechnology Co., Ltd. | 3131 | 2022-12-09 | 2023-07-21 |
| Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years 9-valent HPV vaccine - HPV Infections, Cervical Cancer | Phase 3 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 1200 | 2021-05-28 | 2024-04-17 |
| Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9 - HPV Infections, Cervical Cancer | Phase 3 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 1200 | 2020-09-19 | 2023-11-24 |
| Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL® - Cervical Cancer, Vulvar Cancer | Phase 3 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 1680 | 2020-05-28 | 2022-02-25 |
| Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL® - Cervical Cancer, Vulvar Cancer | Phase 3 | Recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 8000 | 2020-04-28 | 2024-06-07 |
Condylomata Acuminata (5) · Uterine Cervical Neoplasms (5) · Vaginal Neoplasms (4) · Vulvar Neoplasms (4) · Papillomavirus Infections (2)
Communicable Diseases (5) · DNA Virus Infections (5) · Disease Attributes (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5) · Infections (5) · Neoplasms (5) · Neoplasms by Site (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Sexually Transmitted Diseases (5) · Sexually Transmitted Diseases, Viral (5)
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (2) · Vaccines, Synthetic (2)
Shanghai Bovax Biotechnology Co., Ltd. (5) · Biocells (Beijing) Biotech Co.,Ltd (1)
China (6)